Medpace Holdings Inc. (MEDP) 今日夜盘股价大幅上涨15.54%，引起了市场的广泛关注。
消息面上，公司公布了强劲的第二季度财务业绩，各项核心指标全面超越市场预期。具体来看，第二季度每股收益为4.25美元，超出分析师预期约7%；营收达到7.073亿美元，同样高于市场预期。此外，公司新业务订单同比增长显著，净订单出货比表现健康。更为重要的是，公司基于当前的良好势头，上调了全年营收和每股收益的业绩指引，这极大地增强了投资者对公司未来增长潜力的信心。
Medpace是全球领先的临床合同研究组织（CRO），专注于为生物技术、制药和医疗器械行业提供全流程临床开发服务。此次业绩超预期与指引上调的双重利好，是推动其夜盘股价大涨的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.